Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors
about
Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of Lamivudine-resistant mutantsIn vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracilThe polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistanceCross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virusMolecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC).Characterization of novel human hepatoma cell lines with stable hepatitis B virus secretion for evaluating new compounds against lamivudine- and penciclovir-resistant virus.Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitroResistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation.Current pharmacotherapy for hepatitis B infection.Current status of antiviral therapy for hepatitis BChronic hepatitis B: current and future treatment options.Investigational pharmacologic treatment for liver disease.Hepatitis B virus resistance to lamivudine and its clinical implications.Generation of stable cell lines expressing Lamivudine-resistant hepatitis B virus for antiviral-compound screening.Adefovir dipivoxil in the treatment of chronic hepatitis B.In vitro study of the effects of precore and lamivudine-resistant mutations on hepatitis B virus replication.Entecavir for the treatment of chronic hepatitis B.Discovery of a Novel Mutation (X8Del) Resulting in an 8-bp Deletion in the Hepatitis B Virus X Gene Associated with Occult Infection in Korean Vaccinated Individuals.Drug insight: Nucleoside and nucleotide analog inhibitors for hepatitis B.Assessment of Adherence to Prescribed Therapy in Patients with Chronic Hepatitis B.Drug safety evaluation of adefovir in HBV infection.Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains.Kinetic analysis of wild-type and YMDD mutant hepatitis B virus polymerases and effects of deoxyribonucleotide concentrations on polymerase activity.Novel nucleoside analogue MCC-478 (LY582563) is effective against wild-type or lamivudine-resistant hepatitis B virus.JSH Guidelines for the Management of Hepatitis B Virus Infection.Hepatitis B virus genotyping among chronic hepatitis B patients with resistance to treatment with lamivudine in the City of Ribeirão Preto, State of São Paulo.Lamivudine for hepatitis B after liver transplantation.Mechanism of antiviral activities of 3'-substituted L-nucleosides against 3TC-resistant HBV polymerase: a molecular modelling approach.Early emergence of entecavir-resistant hepatitis B virus in a patient with hepatitis B virus/human immunodeficiency virus coinfection.
P2860
Q24563991-712E1297-01D6-4A8D-BC1E-13ED5ED529C0Q28345952-22157CFD-E0B4-4B27-9F8D-10BC7030F7F6Q28350136-6E5062B5-1262-4177-8251-17F52279F342Q28365198-B64F1C7F-79A1-4377-AC21-3C4A34E9D1ECQ33840970-1260F885-6987-44A6-A79F-8E247CFC1A4BQ33981009-489FDD00-FCC2-42B5-864A-6DA76BC530D3Q34112556-0F00EB03-6F43-406B-8D3D-9CFFA0F8470FQ34299035-BFAA8438-2E76-4FE0-BEC5-0765111DC561Q34390231-C9EB5517-1A7E-4945-95C6-11C58A63B95EQ34408879-3DA4C009-C97D-474E-80AA-1F48146474F6Q34687438-828643AC-987B-4028-AE32-E2CF106DF8D2Q34841865-AA5833BC-4E75-4D44-BB63-04A0BB8DC82CQ35007583-BA3312A7-6E40-4E7A-B599-4E684CABACA2Q35014297-8A328094-A9EB-4257-9DB5-DBEAB87F88BFQ35678267-23C44CDE-E95C-42FD-BF4B-2FD5F0B737B3Q35785174-F7013A47-213B-4E0D-A68A-57A83F077150Q35964745-C56B4B92-2F4A-4123-BD13-62BEBDDD8EC9Q36122062-07735857-D788-4AF9-B20C-D1C44581C7E8Q36304057-74BF5F7A-819A-4DF5-B662-458DA389E4D2Q36740003-B059841A-0069-4929-BEA7-F12EAF3F893DQ37889298-67B5986F-7ACA-46C1-B839-80965CDE98B5Q39649139-F69DF393-01EF-4CEE-BC4F-BF8229EB69C8Q39651471-BB50DF1A-D901-4374-ABDF-CC13AADE63AAQ39652342-CDBD4AF3-9F71-40FF-85F9-82817BFC0DB6Q42244740-4AB3EEDC-5098-433E-ACBF-E4EC67602A21Q43012086-E16AE11C-E47D-4ECD-83ED-DD499853C4F2Q43666869-593BBAC4-CFE2-4A0E-99A8-A4591A251148Q44767628-E16E57A4-55FC-4C5C-B905-ED32726E026FQ45398766-8B17F147-C35E-4424-8C3C-4CAD3D844ACC
P2860
Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Susceptibility of lamivudine-r ...... verse transcriptase inhibitors
@ast
Susceptibility of lamivudine-r ...... verse transcriptase inhibitors
@en
Susceptibility of lamivudine-r ...... verse transcriptase inhibitors
@nl
type
label
Susceptibility of lamivudine-r ...... verse transcriptase inhibitors
@ast
Susceptibility of lamivudine-r ...... verse transcriptase inhibitors
@en
Susceptibility of lamivudine-r ...... verse transcriptase inhibitors
@nl
prefLabel
Susceptibility of lamivudine-r ...... verse transcriptase inhibitors
@ast
Susceptibility of lamivudine-r ...... verse transcriptase inhibitors
@en
Susceptibility of lamivudine-r ...... verse transcriptase inhibitors
@nl
P2093
P2860
P356
P1476
Susceptibility of lamivudine-r ...... verse transcriptase inhibitors
@en
P2093
F J Carrilho
S K Ono-Nita
Y Shiratori
P2860
P304
P356
10.1172/JCI5882
P407
P577
1999-06-01T00:00:00Z